Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
The Parkinsons Complex: Parkinsonism Is Just the Tip of the Iceberg
Ann Neurol 59:591-596, Langston,J.W., 2006
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Involuntary Movements After Anterior Cerebral Artery Territory Infarction
Stroke 32:258-261, Kim,J.S., 2001
Bent Spine Syndrome
JNNP 60:51-54, Serratrice,G.,et al, 1996
Idiopathic Hemiparetic Parkinsonism, A Syndrome Distinct from Idiopathic Parkinsonism
Lancet 339:149-150, DeKeyser,J.,et al, 1992
Delayed Cyanide Induced Dystonia
JNNP 55:198-199, Valenzuela,R.,et al, 1992
Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991
Tetrabenazine Therapy of Dystonia, Chorea, Tics, & Other Dyskinesias
Neurol 38:391-394, Jankovic,J.&Orman,J., 1988
Elevated Manganese Levels Associated with Dementia & Extrapyramidal Signs
Neurol 27:213, Banta,R.G.,et al, 1977
Normocalcemic Tetany
Neurol 26:825, Isgreen,W.P., 1976
Neurologic Complications of Heroin Addiction
Bull NY Acad Sci 49:4, Ritcher,R.W.,et al, 1973
Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinsons Disease
NEJM 383:2501-2513,2582, Martinez-Fernandez, R.,et al, 2020
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Thalamic Deep Brain Stimulation for Tremor in Parkinson Disease, Essential Tremor, and Dystonia
Neurol 89:1416-1423, Cury, R.G.,et al, 2017
Clinical, Genetic, and Radiological Features of Extrapyramidal Movement Disorders in Mitochondrial Disease
JAMA Neurol 73:668-674, Martikainen, M.H.,et al, 2016
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Facial Bradykinesia
JNNP 84:681-685, Bologna, M.,et al, 2013
Incidence and Pathology of Synucleinopathies and Tauopathies Related to Parkinsonism
JAMA Neurol 70:859-866, Savica, R.,et al, 2013
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Diagnosis and Treatment of Psychogenic Parkinsonism
JNNP 82:1300-1303, Jankovic, J., 2011
A Multidisciplinary Study of Patients with Early-Onset PD with and Without Parkin Mutations
Neurol 72:110-116,106, Lohmann,E.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Association of Olfactory Dysfunction With Risk for Future Parkinsons Disease
Ann Neurol 63:167-173,132, Ross,G.W.,et al, 2008
Deep Brain Stimulation
Neurologist 13:237-252, Kem,DS. &Kumar,R., 2007
Parkinsons Disease and Genetics
The Neurologist 12:240-244, Lester,J.&Otero-Siliceo,E., 2006
The Pull Test:A History
Mov Disord 21:894-899, Hunt,A.L.,et al, 2006
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005
Pallidal vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Arch Neurol 62:554-560,533, Anderson,V.C.,et al, 2005
Excessive Daytime Sleepiness and Subsequent Development of Parkinson Disease
Neurol 65:1442-1446, Abbott,R.D.,et al, 2005
Ophthalmologic Features of Parkinson's Disease
Neurol 62:177-180, Biousse,V.,et al, 2004
Monoamine Oxide Type B Inhibitors in Early Parkinson's Disease:Meta-Analysis of 17 Randomised Trials Involving 3525 Patients
BMJ 329:593-596, Ives,N.J.,et al, 2004
Post-Stroke Movement Disorders; Report of 56 Patients
JNNP 75:1568-1574, Alarcon,F.,et al, 2004
Does This Patient Have Parkinson Disease?
JAMA 289:347-353, Rao,G.,et al, 2003
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Therapies for Movement Disorders
Arch Neurol 59:699-702, Goetz,C.G &Hinson,V.K., 2002
Parkinsonism as the Presenting Manifestation of HIV Infection: Improvement on HAART
Neurol 56:278-279, Hersh,B.P.,et al, 2001
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
NEJM 344:710-719,763, Freed,C.R.,et al, 2001
Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson's Disease
NEJM 345:956-963, The Deep-Brain Stimulation for Parkinson's Disease, 2001
Complete Genomic Screen in Parkinson Disease
JAMA 286:2239-2244, Scott,W.K.,et al, 2001
Association Between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
NEJM 342:1560-1567, Lucking,C.B.,et al, 2000
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Neurologic Side Effects in Neuroleptic-Naive Patients Treated with Haloperidol or Risperidone
Neurol 52:782-785, Rosebush,P.I.&Mazurek,M.F., 1999
Diagnostic Criteria for Parkinson Disease
Arch Neurol 56:33-39, Gelb,D.J.,et al, 1999
Clinical Correlates of Vascular Parkinsonism
Arch Neurol 56:98-102, Winikates,J.&Jancovic,J., 1999